TIGIT and head and neck squamous cell carcinoma: However, the observed co-expression gives further rationale for using a combination of immune checkpoint inhibitors such as anti-PD-1/anti-TIGIT or anti-PD-1/anti-CTLA-4 in the neoadjuvant setting for treatment of HNSCC.